Claims
- 1. A method of normalizing sexual response in a subject, comprising administering to a subject in need thereof an anti-hypertensive therapy and a centrally-acting dopaminergic agonist, such that sexual response is normalized.
- 2. The method of claim 1, wherein the subject is a human male.
- 3. The method of claim 1, wherein the subject is a human female.
- 4. A method of ameliorating female sexual dysfunction in a subject comprising administering to a female subject in need thereof an anti-hypertensive therapy and a centrally-acting dopaminergic agonist, such that female sexual dysfunction is ameliorated.
- 5. The method of claim 4, wherein the female sexual dysfunction is female sexual arousal disorder.
- 6. A method of ameliorating male sexual dysfunction in a subject comprising administering to a male subject in need thereof an anti-hypertensive therapy and a centrally-acting dopaminergic agonist, such that male sexual dysfunction is ameliorated.
- 7. The method of claim 6, wherein the male sexual dysfunction is penile erectile dysfunction.
- 8. A method of enhancing the efficacy of a centrally-acting dopaminergic receptor agonist in the treatment of sexual dysfunction, comprising administering to a subject in need thereof an anti-hypertensive therapy and centrally-acting dopaminergic receptor agonist.
- 9. The method of claim 1, wherein said anti-hypertensive therapy comprises administration of an ACE inhibitor over a period of time ranging between about five days to about 21 days at a dose ranging between about 1 mg to about 300 mg per kg of body weight per day.
- 10. The method of claim 9, wherein said ACE inhibitor is enalapril, and said enalapril is administered at a dose of about 30 mg per kg of body weight per day.
- 11. The method of claim 9, wherein said dopaminergic receptor agonist is apomorphine or a pharmaceutically acceptable salt or ester thereof, administered on an as-needed basis.
- 12. The method of claim 11, wherein said apomorphine is administered in an amount between about 25 μg/kg of body weight and about 80 μg/kg of body weight.
- 13. The method of claim 11, wherein the plasma concentration of apomorphine is maintained at a level no more than about 5.5 ng/ml.
- 14. The method of claim 11, wherein said apomorphine is administered via a route selected from subcutaneous, intramuscular, transdermal, sublingual, buccal, intranasal, vaginal, and rectal.
- 15. The method of claim 1, wherein the anti-hypertensive therapy and the centrally-acting dopaminergic agonist are administered at the same time.
- 16. The method of claim 15, wherein the anti-hypertensive therapy and the centrally-acting dopaminergic antagonist are administered together as a single dosage unit.
- 17. The method of claim 16, wherein the anti-hypertensive therapy is an ACE inhibitor and the centrally-acting dopaminergic antagonist is apomorphine or a pharmaceutically acceptable salt or ester thereof.
- 18. A pharmaceutical composition comprising a single dosage unit of an anti-hypertensive therapy and a centrally-acting dopaminergic antagonist together with a pharmaceutically acceptable carrier therefore.
- 19. The pharmaceutical composition of claim 19, wherein the anti-hypertensive therapy is selected from the group consisting of ACE inhibitors, angiotensin II receptor antagonists, calcium channel blockers, α1-adrenergic receptor antagonists, β-adrenergic receptor antagonists, and endothelin receptor antagonists, and the centrally-acting dopaminergic antagonist is apomorphine or a pharmaceutically acceptable salt or ester thereof.
- 20. The composition of claim 19, wherein the anti-hypertensive therapy is an ACE inhibitor.
RELATED APPLICATIONS
[0001] This application claims the benefit of the filing date of U.S. Provisional Patent Application No. 60/417,166, filed Oct. 10, 2002, the contents of which are incorporated herein by reference in their entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60417166 |
Oct 2002 |
US |